AbbVie Inc. $ABBV Shares Newly Purchased by Capstone Capital Management Ltd

Key Points

• Capstone Capital Management purchased 3,772 AbbVie shares worth approximately $987,000 in the third quarter, while institutional investors and hedge funds collectively own 70.23% of the stock.
• AbbVie reported quarterly EPS of $3.65, exceeding estimates, with revenue rising 10.2% year over year to $16.99 billion. Analysts maintain a “Moderate Buy” consensus and an average price target of $278.07.
• The company declared a quarterly dividend of $1.73 per share, equivalent to an annualized $6.92 dividend and a 2.4% yield, though its payout ratio is elevated at 195.48%.

Capstone Capital Management Ltd bought a new stake in AbbVie Inc. (NYSE:ABBV - Free Report) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 3,772 shares of the company's stock, valued at approximately $987,000.

Several other hedge funds have also bought and sold shares of the company. Range Financial Group LLC raised its stake in AbbVie by 2.4% in the 3rd quarter. Range Financial Group LLC now owns 5,565 shares of the company's stock valued at $1,456,000 after acquiring an additional 130 shares during the period. Newman Dignan & Sheerar Inc. boosted its position in AbbVie by 57.9% during the third quarter. Newman Dignan & Sheerar Inc. now owns 6,547 shares of the company's stock worth $1,713,000 after purchasing an additional 2,400 shares during the period. Benchmark Financial Wealth Advisors LLC boosted its position in AbbVie by 11.0% during the third quarter. Benchmark Financial Wealth Advisors LLC now owns 4,309 shares of the company's stock worth $1,127,000 after purchasing an additional 428 shares during the period. Cushing Capital Partners LLC bought a new position in AbbVie during the third quarter worth $242,000. Finally, Physician Wealth Advisors Inc. increased its holdings in shares of AbbVie by 11.3% in the third quarter. Physician Wealth Advisors Inc. now owns 1,531 shares of the company's stock valued at $401,000 after purchasing an additional 155 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the business's stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president owned 74,430 shares of the company's stock, valued at approximately $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.06% of the company's stock.

AbbVie Trading Down 1.5%

NYSE:ABBV opened at $284.63 on Thursday. The stock has a market cap of $502.89 billion, a P/E ratio of 80.41, a PEG ratio of 1.32 and a beta of 0.24. The stock has a 50 day simple moving average of $264.93 and a 200 day simple moving average of $240.92. AbbVie Inc. has a 1-year low of $190.75 and a 1-year high of $291.40.

AbbVie (NYSE:ABBV - Get Free Report) last released its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The business had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. During the same period in the previous year, the company posted $2.97 EPS. The firm's quarterly revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, sell-side analysts forecast that AbbVie Inc. will post 13.94 EPS for the current year.

AbbVie Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be given a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date of this dividend is Thursday, October 15th. AbbVie's payout ratio is presently 195.48%.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie reported encouraging Phase 2a data for ABBV-466, an investigational combination treatment for Crohn’s disease. The therapy reportedly outperformed Skyrizi alone, strengthening the company’s immunology pipeline and helping offset concerns about the eventual loss of exclusivity for Humira. AbbVie’s Crohn’s Combo Topped Skyrizi Alone in a Phase 2a Trial
• Positive Sentiment: Allergan Aesthetics, AbbVie’s aesthetics business, presented new and long-term evidence for HArmonyCa, JUVÉDERM, SKINVIVE and BOTOX Cosmetic. Continued product adoption and clinical support could aid growth in the aesthetics segment. Allergan Aesthetics Deepens Science Behind Multimodal Approach
• Positive Sentiment: The company launched a multiyear partnership with McLaren Racing, including the “AbbVie Race to Innovate” patient-advocacy campaign. The agreement is primarily a branding initiative, but it may increase awareness of AbbVie’s immunology franchise. McLaren Racing Announces Partnership With AbbVie
• Neutral Sentiment: Analyst comparisons continue to highlight AbbVie’s revenue growth, strong free cash flow and dependable dividend increases. However, the stock’s elevated valuation after its rally leaves less room for disappointment.
• Negative Sentiment: AbbVie halted a Phase 1b combination trial for early-stage liver cancer. Because the study was in an early development stage, the direct financial impact may be limited, but the decision removes a potential pipeline opportunity and likely weighed on sentiment. AbbVie Halts Early-Stage Liver Cancer Combo Trial

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. Cantor Fitzgerald increased their price objective on shares of AbbVie from $285.00 to $290.00 and gave the company an "overweight" rating in a research report on Thursday, October 8th. Argus raised their target price on shares of AbbVie from $250.00 to $270.00 in a research note on Tuesday, August 4th. Piper Sandler lifted their target price on shares of AbbVie from $298.00 to $303.00 and gave the stock an "overweight" rating in a report on Thursday, August 20th. Rothschild & Co Redburn upped their price target on shares of AbbVie from $284.00 to $285.00 and gave the company a "buy" rating in a research note on Tuesday, August 4th. Finally, Royal Bank Of Canada reiterated an "outperform" rating and issued a $280.00 price target on shares of AbbVie in a research note on Tuesday, October 13th. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $278.07.

About AbbVie

AbbVie Inc NYSE: ABBV is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company's key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.